Akums Drugs and Pharmaceuticals Ltd., India’s Larget Contract Development and Manufacturing Organization (CDMO), Has Announced ITS Consolidated Financial Results for the Quore and The Quar 2025. This Quarter Continued to Display Strong Performance with Healthy Growth in Adj Ebitda and adj pat.
In Q1 FY26, Akums Reported Total Income of Rs. 1,051 Crore, with Healthy adj ebitda of Rs. 156 Crore Reflecting a Robust 19.1% Year-On-Year (Yoy) Growth. The margins improved to 14.8% from 12.7% last year a 208 BPS improvement.
DURING this Quarter, The company achieved a key millstone of Reaching 1,000 Drug Controller General of India (DCGI) Approvals, with 27 Fresh Approvals in this Quarter. The DCGI Approves Assist The Company in Enhancing Its Product Mix, Building a Differentiated and Research-Driven portfolio. Additional, the company also received a patent for its extended-Release Combination Formulation of Doxylamine and Pyridoxine Developed Using The Company’s Tablet in Tablet Technology.
As part of Akums’ Strategic Vision to Establish Itself as a Leading Global CDMO, The Company Received Its First Eu Dossier Approval for Rivaroxaban. It also filled its first dossier of dapagliflozin combination in Switzerland. Both of these new products hold significant market potential. The Commercialization of the Eu Contract also Continues to be on Track and the Company will commence commercial supplies from Aware 2027.
Akums Received 100 Mn Euros as Part Consideration for the Eu Contract in Q1 This year, consutenly the company is at a cash surplus of Rs. 1,518 cr. The Strong Liquidity Position Provides a Robust Foundation for Akums to Strategically Scale Up Its Business Operations Through Organic Growth Initiatives and Inorganic Opportunities.
Segmental Performance Overview
Akums’ Flagship business, CDMO, Contributed ~ 79% to the group turns with an ebitda of 14.7% in q1 fy 26. The company’s domestic branded formulation bushes segment replies International Branded Formulation Business Grew By ~ 2% Yoy. Trade geneerics and api segment continue to be in operational loss this Quarter, Thought, Through the Management Efforts, the losses are gradually reducing.
Commenting on the results, Mr. Sanjeev jain, managing directorSaid, “This date marks just over one year since we get listed. We continue to work towards strengthening the organization with a focus on long term growth. Our Commitment to becoming a global CDMO Player Remains Steadfast. The recent filings along with the planned global approvals of other facilites are setting up us in that endavor,
Mr. Sandeep Jain, Managing DirectorAdded, “We Continue to Deliver Strong Performance Despite The Industry Headwinds of Decreasing API Pries and MUTED Volume Growth. With a sustained focus on r & d, we have been able to deliver robust growth. Achieving 1,000 DCGI Approves is a Key Milestone that Stands Out Akums from its peers, allowing akums to offer margin accountive differentted offerings. We Remain focused on Strengthening Our CDMO Leadership, Scaling High-Value Capability, and Driving Operational Excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years Ahead,
Extract of Consolidated Financial Results
| Particulars (RS CR) | Q1 fy 26 | Q4 fY 25 | Q1 fy 25 |
| Revenue | 1,024 | 1,056 | 1,019 |
| Other income | 27 | 18 | 7 |
| Total Income | 1,051 | 1,073 | 1,026 |
| Cost of Goods Sold | 582 | 639 | 596 |
| Employee Cost | 176 | 184 | 176 |
| Other Expenses | 137 | 139 | 123 |
| Adj ebitda | 156 | 111 | 131 |
| Adj ebitda margin | 14.8% | 10.4% | 12.7% |
| Adj pat | 65 | 44 | 57 |
| Adj pat margin | 6.2% | 4.1% | 5.6% |
Definitions
Adjusted ebitda has been invised as the sum of profit Items.
Adjusted pat is called as the profit for the Quarter Plus Fair Value Changes to Financial Instruments Less Tax Deferred Tax Created on Burgt Forward Losses.
CDMO: Contract Development and Manufacturing Operations
API: Active Pharmaceutical ingredients
